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Abstract 
An anesthesia drug display that shows the predicted 
effects of medication may be extremely useful on a 
space station and in situations where an inexperienced 
person could be performing experiments on animals or 
emergency treatments to fellow astronauts. Such a drug 
display shows drugs given and predicts their effects on 
the person or animal. In order for such a display to be 
useful, the predictions must be validated to ensure 
accuracy of and instill confidence in those who use the 
display. This study consists of validation ofrocuronium 
which is a drug used for neuromuscular blockade 
(muscle relaxation). The effects of this drug have 
currently been studied on 12 patients. Qualitatively, the 
effects of this drug appear to be in line with the kinetic 
model predictions. Data will be gathered from more 
patients and will be statistically analyzed and compared 
with the model predictions for validation. 
Introduction 
On the space station, animals may be put to sleep for 
biology experiments such as dissections or small 
implant surgeries. Humans may also be anesthetized in 
the case of a painful accident. Astronauts come from all 
disciplines and rarely, if ever, are trained in 
anesthesiology. An anesthesia display such as the one 
developed in our lab (Fig. 1) could be extremely useful 
in such a situation. Either the drugs given can be 
automatically tracked or the astronauts could enter the 
information by hand, stating what drug was given at 
what time. The anesthesia drug display could then 
calculate in real time what the predicted effects of the 
drug are on the animal or astronaut. 
Figure 1. Anesthesia Drug Display Prototype. The 
bottom line shows an example of the muscle 
relaxants. 
The drug display currently shows the administration 
and effects of three different drugs: measuring 
sedation, pain, and muscle relaxation. The y-axes of 
the graphs show the amount of drug, and the x-axes 
are time. The vertical lines show a bolus of the drug, 
and then the solid line is the predicted drug effect site 
concentration (from the model). The dotted lines 
show what the drug levels will be in the near future, 
allowing time for the anesthesiologist to better think 
ahead and adjust medications if necessary. On the far 
right of the display, the predicted clinical effect is 
shown. 
During surgery or any kind of serious treatment 
anesthesia may be used for sedation (rendering the 
patient unconscious and unaware of their 
surroundings), analgesia (pain medication), or for 
neuromuscular blockade (muscle relaxation). The 
drug display shows this information in real time and 
may eventually adapt to specific patients due to age, 
weight, height, gender, and drug sensitivity levels. 
The plot on the left shows the drug concentrations 
predicted in the subject's body, while the plot on the 
right shows the predicted effect of the patient to the 
drug given. In the case of muscle relaxants, a 
commonly used measure of effect called Train-of-
four (TOF) is displayed. 
The purpose of relaxing a patient is to avoid 
unwanted muscular responses. One example ofthis is 
intubation '. As the anesthesiologist places a tube 
down the patient's throat and connects it to a 
ventilator, the patient may have a gag reflex. Another 
possible reaction would be contractions in the 
abdomen due to a surgical stimulus'. The doctor does 
not want a person's (or animal's) abdomen to 
contract while he has sensitive surgical instruments 
(i.e. a knife) in the area. Muscle relaxants 
(neuromuscular blocking agents) suppress reactions 
like this to allow easier care and management by 
healthcare professionals2• 
Monitoring of neuromuscular blockade and its effects 
is most often accomplished with train off our 
stimulation and measurement. TOF measurement 
consists of four short stimulations, which cause the 
adductor pollicis (thumb and index finger) to twitch 
four times3. As the muscle relaxant takes effect, the 
patient response reduces to three twitches, then two, 
one, and finally zero. At zero twitches the 
neuromuscular blockade is in full effect and the patient 
is very relaxed and muscles should not respond to a 
given stimuli. At four twitches the TOF ratio is used. 
This is a measure of the strength ofthe fourth twitch 
divided by the strength of the first twitch. Using this 
measure allows more fidelity in determining how close 
to normal a person is with respect to neuromuscular 
function. A ratio of 100 percent means that their 
neuromuscular function is normal and they have four 
full twitches. The lower the ratio, the more relaxed a 
person is and the weaker they feel and respond to a 
given stimulus. 
The models used to predict patient reactions to the drug 
can be split into two categories: pharmacokinetic and 
pharmacodynamic4• Pharmacokinetic models are those 
that predict the concentration of the drug in the patient, 
and the pharmacodynamic models take this drug 
concentration and predict an effect on the patient at any 
given concentration. 
The pharmacokinetic model used in this study is the 
Plaud two compartment model. The two compartments 
are the bloodstream and the effect site in the body. The 
model includes parameters which account for 
equilibration between these compartments. The drug 
display is the same implementation as Stanpump, a well 
known anesthesia modeling simulation 
The pharmacodynamic model used this study is still 
being developed. The first step to this development is 
using the Hill equation to calculate the strength of the 
fIrSt twitch (from the effect site drug concentration, at 
the hand)3. From this information the train of four count 
and then ratio may be calculated. 
Methods 
To date there have been 12 subjects, out of a total of24 
for the study. The patient population is a healthy set of 
laparoscopic patients (most are gall bladder removals 
and hernias). Data collected includes all drugs given to 
the patient, as well as vital signs such as blood pressure, 
heart rate, and any patient responses throughout the 
surgery. The neuromuscular data consists of train-of-
four monitoring with the Datex-Ohmeda Electrosensor 
and NMT module. 
During preparation for surgery in the operating room, 
the sensor is placed on the patient's thumb and index 
finger and taped in place. A temperature sensor is 
placed on the palm, and the arm is then wiped with an 
alcohol pad to remove oil from the skin and allow better 
electrode performance. As soon as the patient loses 
consciousness, the electrodes are placed on the arm at 
the ulnar nerve (a mini stimulator is used to ensure 
that the nerve is found and the electrodes are placed 
optimally). Figure 2 shows the electrode and sensor 
placement. The monitor calibrates the sensor by 
finding the supramaximal current with 100 Ilsec 
pulses. Train-of-four measurements are taken at 20-
second intervals throughout the case. Before the 
patient regains consciousness, the sensor and 
electrodes are taken off of the patient. 
Figure 2. Train of four stimulator and sensor. 
(Image source www.datex-ohmeda.com.) 
Throughout the surgery data is collected with a 
laptop through Rugloop, which is a program that 
collects all data from the Datex monitor. 
Preliminary Results and Conclusions 
The following graphs are of one patient's 
neuromuscular data throughout a surgery. This 
specific set of graphs is comparable to the others in 
the dataset. Currently the analysis has taken into 
consideration the tl ratio, TOF count, and TOF ratio. 
The first important graph (Figure 3) shows the times 
that the drugs were administered. In this case there 
was a bolus ofrocuronium at the beginning of the 
case (the spike at about 700 seconds). The spike at 
the end of the case is due to administration ofa 
reversal agent, neostygmine. 
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Figure 3. Drug administration. The first spike is due 
to the muscle relaxant, rocuronium. The second 
spike is the reversal agent, neostygmine. 
The tI ratio shows the strength of the first twitch to the 
baseline/calibrated value. This measure shows the quick 
onset of muscle relaxation effects, as soon as 
rocuronium was delivered. It is clear that before 
rocuroruum administration, the twitch was at or near 
100% of its original value. There is a slight delay after 
administration but then this twitch quickly disappears 
(Figure 4). The slow return of a full strength twitch as 
the effects of the drug wear off is also apparent. 
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Figure 4. The tl ratio is shown above. This is the 
quantitative value showing the strength of the first 
twitch. Note that it declines rapidly and then 
recovers more slowly. 
The phannacokinetic model used to predict drug 
concentrations is the Plaud model, and the drug display 
has been tested against the Stanpump implementation 
for accuracy. Figure 5 shows the pharmacokinetics 
predicted throughout the case. These drug concentration 
levels are what is shown on the drug display. 
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Figure 5. Effect site drug concentration calculated 
with the Plaud pharmacokinetic model. Train of 
four count is also shown. Note that as the drug 
levels are high, the number oftwitches decrease, 
and that there is a slight delay in this process. 
At the beginning of the surgery, the patient had 4 
twitches showing that their neuromuscular function is 
normal. As predicted drug levels increase, there is a 
slight delay but the twitch count decreases as the 
patient's reflexes decrease. The twitch count rises as 
drug concentration levels decline and the 
neuromuscular function returns to normal. 
At the point where there are four twitches, the train of 
four ratio is used. This is a measure of the strength of 
the fourth twitch divided by the strength of the fIrst 
twitch. As the muscle relaxant begins to effect the 
patient, this ratio decreases. The ratio increases to 
100% when neuromuscular function returns to 
norinal. Figure 6 shows the results of this 
measurement. 
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Figure 6. TOF ratio. Zeros are when the TOF 
count was less than four. Note that this ratio drops 
off sharply and rises back up slowly. 
There is a slight delay after rocuronium administration, 
but the ratio does decline rapidly as the muscles 
become relaxed. The ratio slowly increases toward 
normal function until the reversal agent is given. This 
information is consistent with the characteristics of 
rocuronium I. Once this occurs the slope sharply 
increases as neuromuscular function quickly returns to 
normal. In this case the data ends at 60% recovery due 
to shutting off the equipment. (This maximizes patient 
comfort as they wake up from the anesthesia). 
A qualitative look at these results are promising for 
drug model validation. Some work will be done to look 
at the pharmacodynamic model of predicted TOF count 
vs. actual TOF count. Statistical methods of analyzing 
the data are being explored and will be performed soon. 
Future Work 
Once the drug models are validated, the display will be 
tested in the operating room to show that this is an 
extremely valuable tool. Models may also be adapted 
according to patient parameters such as height, weight, 
and age. This will make the display patient specific and 
therefore more accurate and useful. 
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